<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28288570</article-id><article-id pub-id-type="pmc">5347830</article-id><article-id pub-id-type="publisher-id">501</article-id><article-id pub-id-type="doi">10.1186/s12882-017-0501-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Al Therwani</surname><given-names>Safa</given-names></name><address><phone>+45 31515473</phone><email>safatherwani@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rosenb&#x000e6;k</surname><given-names>Jeppe Bakkestr&#x000f8;m</given-names></name><address><email>jepros@rm.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mose</surname><given-names>Frank Holden</given-names></name><address><email>frank.holden.christensen@vest.rm.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Bech</surname><given-names>Jesper N&#x000f8;rgaard</given-names></name><address><email>jesper.noergaard.bech@vest.rm.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Erling Bjerregaard</given-names></name><address><email>mail@ebped.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution>University Clinic in Nephrology and Hypertension, Department of Medical Research, Holstebro Hospital, </institution><institution>Aarhus University, </institution></institution-wrap>Hospital Unit Jutland West, Laegaardvej 12, 7500 Holstebro, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>86</elocation-id><history><date date-type="received"><day>28</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>7</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Tolvaptan is a selective vasopressin receptor antagonist. Nitric Oxide (NO) promotes renal water and sodium excretion, but the effect is unknown in the nephron&#x02019;s principal cells. In a dose-response study, we measured the effect of tolvaptan on renal handling of water and sodium and systemic hemodynamics, during baseline and NO-inhibition with L-NMMA (L-NG-monomethyl-arginine).</p></sec><sec><title>Methods</title><p>In a randomized, placebo-controlled, double blind, cross over study, 15 healthy subjects received tolvaptan 15, 30 and 45&#x000a0;mg or placebo. L-NMMA was given as a bolus followed by continuous infusion during 60&#x000a0;min. We measured urine output (UO), free water clearance (C<sub>H2O</sub>), fractional excretion of sodium (FE<sub>Na</sub>), urinary aquaporin-2 channels (u-AQP2) and epithelial sodium channels (u-ENaC&#x003b3;), plasma vasopressin (p-AVP) and central blood pressure (cBP).</p></sec><sec><title>Results</title><p>During baseline, FE<sub>Na</sub> was unchanged. Tolvaptan decreased u-ENaC<sub>&#x003b3;</sub> dose-dependently and increased p-AVP threefold, whereas u-AQP2 was unchanged. During tolvaptan with NO-inhibition, UO and C<sub>H2O</sub> decreased dose-dependently. FE<sub>Na</sub> decreased dose-independently and u-ENaC<sub>&#x003b3;</sub> remained unchanged. Central BP increased equally after all treatments.</p></sec><sec><title>Conclusions</title><p>During baseline, fractional excretion of sodium was unchanged. During tolvaptan with NO-inhibition, renal water excretion was reduced dose dependently, and renal sodium excretion was reduced unrelated to the dose, partly via an AVP dependent mechanism. Thus, tolvaptan antagonized the reduction in renal water and sodium excretion during NO-inhibition. Most likely, the lack of decrease in AQP2 excretion by tolvaptan could be attributed to a counteracting effect of the high level of p-AVP.</p></sec><sec><title>Trial registration</title><p>Clinical Trial no: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02078973">NCT02078973</ext-link>. Registered 1 March 2014.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12882-017-0501-1) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tolvaptan</kwd><kwd>Nitric oxide</kwd><kwd>ENaC</kwd><kwd>AQP2</kwd><kwd>Blood pressure</kwd><kwd>Vasoactive hormones</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Water and salt balance in the body is a result of complex interactions of hormones, especially vasopressin and the components in the renin-angiotensin-aldosterone system. Vasopressin sensitive aquaporin2 water channels and epithelial sodium channels are expressed in the principal cells in the collecting ducts [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Stimulation of vasopressin receptors (V2) facilitates renal absorption of water and sodium [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. This mechanism is antagonized by tolvaptan, a selective V2 receptor antagonist. NO may affect the renal urine concentration mechanism by membrane insertion of AQP2 in the collecting ducts principal cells [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. However, it is debated whether NO inhibits or stimulates AQP-mediated water transport. In a previous study, we showed that NO promotes water excretion by a partly AVP dependent mechanism [<xref ref-type="bibr" rid="CR12">12</xref>]. NO is synthesized from L-arginine by NO-synthase, an enzyme that is competitively inhibited by L-NMMA [<xref ref-type="bibr" rid="CR13">13</xref>]. Systemic NO inhibition causes reduction in diuresis, natriuresis, and increases in blood pressure [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Several studies have documented the effect of selective V2 receptor antagonism on renal sodium and water excretion, but whether NO is involved in the response of the V2 receptors in the renal tubular and vascular function is not clarified. Recently, tolvaptan has been approved by the EMA for treatment of autosomal dominant polycystic kidney disease [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Also, tolvaptan is effective in conditions of dilutional hyponatremia, associated with congestive heart failure, cirrhosis and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. However, The European guideline on hyponatremia recommends against the use of tolvaptan in the clinical management of SIADH [<xref ref-type="bibr" rid="CR27">27</xref>]. Thus, based on a most likely wide spread use of tolvaptan in the future, an in-depth knowledge is necessary regarding the effect of the tolvaptan on renal tubular function, vasoactive hormones and blood pressure. Our laboratory has previously investigated the effect of tolvaptan 15&#x000a0;mg at baseline and during tolvaptan with NO-inhibition in a randomized, placebo-controlled, double-blinded, crossover study [<xref ref-type="bibr" rid="CR12">12</xref>]. We demonstrated a clear effect of tolvaptan 15&#x000a0;mg at baseline and during tolvaptan with NO-inhibition on renal water excretion and the activity in ENaC, but no knowledge is available about the effect of different doses regarding interaction between tolvaptan and NO-inhibition.</p><p>In the present study, we hypothesized 1. that tolvaptan increases water and sodium excretion in a dose-dependent manner, 2. that systemic NO-inhibition reduces this response dose-dependently, and 3. An increase in blood pressure and vasoactive hormones at baseline and during NO-inhibition counteracts tolvaptan&#x02019;s effect on the tubular sodium and water transport at least partially.</p><p>The purpose was to measure the effect tolvaptan on 1. glomerular filtration rate and renal absorption of water and sodium (GFR (<sup>51</sup>Cr-EDTA-clearance), urinary output (UO), free water clearance (C<sub>H2O</sub>), fractional excretion of sodium (FE<sub>Na</sub>), urinary excretion of aquaporin 2 (u-AQP2), and urinary excretion of a protein fragment of the epithelial sodium channel (u-ENaC<sub>&#x003b3;</sub>)<sub>,</sub> 2.blood pressure (brachial blood pressure (Bbp), central BP (cBP), pulse wave velocity (PW), augmentation index (AI)), and 3. vasoactive hormones in plasma(vasopressin (p-AVP), angiotensinII (p-AngII), renin (PRC), and aldosterone (p-Aldo)), both at baseline and during tolvaptan with NO-inhibition in a randomized, placebo-controlled, double-blinded, crossover dose-response study of healthy volunteers.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Subjects</title><sec id="Sec4"><title>Inclusion criteria</title><p>Healthy non-smoking men and women, age between 18 and 40&#x000a0;year. and with BMI between 18.5 and 30&#x000a0;kg/m<sup>2</sup> were enrolled.</p></sec><sec id="Sec5"><title>Exclusion criteria</title><p>Exclusion criteria were; arterial hypertension (bBP&#x02009;&#x0003e;&#x02009;140&#x000a0;mmHg systolic and/or &#x0003e;90&#x000a0;mmHg diastolic), history or clinical signs of neoplastic disease or disease of the heart, lungs, kidneys or endocrine organs, drug or alcohol abuse (I.e.&#x02009;&#x0003e;&#x02009;14 units a week for women and 21 for men), medical treatment except oral contraceptives, pregnancy or breast-feeding, significant laboratory abnormalities in the screening test of blood samples (I.e. abnormal hemoglobin, white cell count, plasma sodium, plasma potassium, plasma creatinine, plasma alanine aminotransferase or serum cholesterol, plasma bilirubin and plasma albumin, and urine samples (I.e. albuminuria or glucosuria), abnormal electrocardiogram, blood donation less than 1&#x000a0;month prior to the study.</p><p>In fertile women contraceptive treatment must be used during and after the study period (I.e. oral contraceptives, spiral, depot injection of gestagen, sub dermal implantation, transdermal contraceptive patch and hormonal contraceptive vaginal ring).</p><p>Withdrawal criteria were development of one or more of the exclusion criteria, brachial blood pressure increase above 180/105&#x000a0;mmHg during infusion of L-NMMA, withdrawal of consent or lack of compliance.</p></sec></sec><sec id="Sec6"><title>Study design</title><p>The trial was performed as a randomized, double-blinded, placebo- controlled, crossover, dose-response study in healthy subjects. The study consisted of four treatment periods, placebo or tolvaptan 15, 30 and 45&#x000a0;mg, with an intermediate wash- out period of at least 3&#x000a0;weeks to eliminate any carryover effects.</p></sec><sec id="Sec7"><title>Medications</title><p>Tolvaptan (SAMSCA&#x000ae;, Otsuka, Tokyo, Japan) 15, 30 and 45&#x000a0;mg or placebo were coated in identical gelatine capsules and were orally administered at 8:00&#x000a0;AM.</p><p>L-NMMA (Bachem, Weil am Rhein, Germany) was dissolved in isotonic saline solution and given intravenously at 11:00&#x000a0;AM.</p></sec><sec id="Sec8"><title>Number of subjects</title><p>Free water clearance (C<sub>H2O</sub>) was used as the main effect variable. With a minimal relevant difference of 6&#x000a0;ml/min with an estimated standard deviation (SD) of 4&#x000a0;ml/min, 12 subjects were needed using a level of significance of 5% and a statistical power of 90%. Due to possible drop outs 15 subjects were included.</p></sec><sec id="Sec9"><title>Recruitment</title><p>Healthy volunteers were recruited by advertising in public institutions and private companies.</p></sec><sec id="Sec10"><title>Effect variables</title><p>C<sub>H2O</sub> was the primary effect variable<sub>.</sub> The secondary effect variables were 1) renal function (<sup>51</sup>Cr-EDTA-clearance, UO, u-AQP2, u-ENaC<sub>&#x003b3;</sub>, FE<sub>Na</sub>), 2) hemodynamics (bBP, cBP, PWV, AI and 3) vasoactive hormones (PRC, p-ANG II, p-Aldo, p- AVP).</p></sec><sec id="Sec11"><title>Diet</title><p>Four days prior to each treatment period subjects consumed a standardized diet of 11.000 KJ day<sup>&#x02212;1</sup>. The diet was delivered from our facilities and was composed of 15% proteins, 55% carbohydrates and 30% fat following general dietary guidelines. The sodium content was 150&#x000a0;mmol&#x000a0;day<sup>&#x02212;1</sup>. No additional sodium or other spices was allowed. The daily fluid intake was 2.5&#x000a0;L including a maximum of two cups of coffee or tea. No alcohol or soft drink was allowed during the 4-day diet.</p></sec><sec id="Sec12"><title>Experimental procedure</title><p>A 24-h urine was collected and a fasting period of 8&#x000a0;h was performed prior to each examination day. The four examinations were conducted at our facility from 7:45&#x000a0;AM to 1:00&#x000a0;PM. The procedures were identical on all examination days.</p><p>At 8:00&#x000a0;AM subjects were given placebo or tolvaptan 15, 30 and 45&#x000a0;mg. An intravenous catheter was placed in each arm to collect blood samples and infuse <sup>51</sup>Cr-EDTA.</p><p>At 8:00&#x000a0;AM and every 30&#x000a0;min, an oral water load of 175&#x000a0;ml was given.</p><p>BP was measured every 30&#x000a0;min from 8:30&#x000a0;AM to 1:00&#x000a0;PM. Based on results from a dose-finding study made by our laboratory in healthy subjects [<xref ref-type="bibr" rid="CR15">15</xref>], a bolus of L-NMMA 4.5&#x000a0;mg/kg was given at 11:00&#x000a0;AM, followed by continuous infusion (3&#x000a0;mg/kg/h) during 60&#x000a0;min. During infusion of L-NMMA BP was measured every 5&#x000a0;min, and every 15&#x000a0;min after infusion of L-NMMA.</p><p>Blood samples were drawn every 30&#x000a0;min from 8:30 to 1:00&#x000a0;PM and were analyzed for p-Na, p-osm, p-creatinine, p-albumin and p-<sup>51</sup>Cr-EDTA. Every 60&#x000a0;min; at 11:00&#x000a0;AM (baseline), at 12:00&#x000a0;AM (after end of L-NMMA infusion), and at 1:00&#x000a0;PM (60&#x000a0;min after end of L-NMMA infusion), blood samples were drawn to measure PRC, p-Aldo, p-Ang II and p-AVP.</p><p>Every 30&#x000a0;min from 9:30&#x000a0;AM to 1:00&#x000a0;PM, urine samples were collected by voiding in standing or sitting position after collecting BP measurements and blood samples. Otherwise subjects were kept in a supine position in a temperature-controlled (22&#x02013;25&#x000a0;&#x000b0;C) and quiet room. Baseline period was mean of the first three clearance periods. The urine samples were analyzed for osmolality, creatinine, sodium, AQP2, ENaC<sub>&#x003b3;</sub> and <sup>51</sup>Cr-EDTA.</p><p>Applanation tonometry with SpygmoCor was performed at 10:10&#x000a0;AM and at11: 40&#x000a0;AM to measure cBP, PVW and AI.</p></sec><sec id="Sec13"><title>Measurements</title><sec id="Sec14"><title>Renal function</title><p>
<sup>51</sup>Cr-EDTA-clearance was measured using the constant infusion clearance technique with 51Cr-EDTA as reference substance.</p><p>C<sub>H2O</sub> was determined using the formula C<sub>H2O</sub>&#x02009;=&#x02009;UO- C<sub>osm</sub>, where C<sub>osm</sub> is the osmolar clearance.</p><p>Clearance (C) of substance X was calculated as C<sub>X</sub>&#x02009;=&#x02009;U<sub>X</sub>/(P<sub>X</sub> x UO), where U<sub>X</sub> denotes concentration of x in urine, P<sub>X</sub> denotes concentration of x in plasma, and UO is urine excretion rate.</p><p>Fractional excretion of sodium was determined according to the following formula FE<sub>Na</sub>&#x02009;=&#x02009;C<sub>Na</sub>/<sup>51</sup>Cr-EDTA-clearance x100%, where C<sub>Na</sub> is sodium clearance.</p></sec><sec id="Sec15"><title>Urinary excretion of AQP2 and ENaC<sub>&#x003b3;</sub></title><p>Urine samples were kept frozen at &#x02212;20&#x000a0;&#x000b0;C until assayed. U-AQP2 and u-ENaC<sub>&#x003b3;</sub> were measured by radioimmunoassay as previously described [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Antibodies were raised in rabbits to synthetic peptide as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]. U-ENaC<sub>&#x003b3;</sub> was measured by radioimmunoassay as previously described [<xref ref-type="bibr" rid="CR29">29</xref>]. Antibodies were raised against the synthetic ENaC<sub>&#x003b3;</sub> peptide in rabbits and affinity purified as described previously [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The anti-AQP2 antibody was a gift from Soerens Nielsen, The Water and Salt Research Center, Institute of Anatomy, Aarhus University, Denmark.</p></sec><sec id="Sec16"><title>Vasoactive hormones in plasma</title><p>Blood samples collected for measurements of vasoactive hormones were centrifuged and plasma was separated, and kept frozen until assayed as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]. PRC was determined by immunoradiometric assay as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]. Aldo was determined by RIA as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]. Ang II and AVP were extracted from plasma and then determined by radioimmunoassay [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec17"><title>Brachial and central blood pressure</title><p>Brachial BP was measured using an oscillometer (Omron 705IT) and recorded as previously described [<xref ref-type="bibr" rid="CR12">12</xref>]. Central BP, PWA and carotid-femoral PWV were measured using applanation tonometry (SphygmoCor&#x000ae; CPV system&#x000ae;, AtCor Medical, Sydney, Australia) as previously described [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec18"><title>Routine analyses</title><p>Sodium, glucose, albumin, and hemoglobin were measured by routine methods in Department of Clinical Biochemistry, Holstebro Hospital.</p></sec><sec id="Sec19"><title>Statistics</title><p>We performed statistical analyses by using IBM SPSS statistics version 20.0.0 (SPSS Inc., Chicago, IL, USA). General Linear Model Repeated Measures was used for comparison between and within subjects to test differences between placebo and tolvaptan treatment at baseline, during and after infusion of L-NMMA. One-way ANOVA was performed for comparison between treatment groups.</p><p>To compare differences between treatment groups at baseline, paired sample <italic>t</italic>-test was performed during and after infusion of L-NMMA. Statistical significance was at &#x0003c;0.05 in all analyses. Data with normal distribution are reported as means&#x02009;&#x000b1;&#x02009;SD or SEM. Non-parametric test was performed for data with non-normal distribution, and are reported as medians with 25th and 75th percentiles.</p></sec></sec></sec><sec id="Sec20"><title>Results</title><sec id="Sec21"><title>Demographics</title><p>Twenty-seven healthy subjects were allocated to the trial. Twelve of the participants were excluded; three due to difficulties to gain intravenous access, two due to arterial hypertension and seven due to withdrawal of consent. Fifteen participants completed the study, three males and 12 females. Median age was 24&#x02009;&#x000b1;&#x02009;2&#x000a0;years, weight 71.8&#x02009;&#x000b1;&#x02009;13.1&#x000a0;kg, BMI 24&#x02009;&#x000b1;&#x02009;4 kgm<sup>2</sup>. P-sodium 141&#x02009;&#x000b1;&#x02009;1.7&#x000a0;mmol/L, p-potassium 3.7&#x02009;&#x000b1;&#x02009;0.2&#x000a0;mmol/L, p-creatinine 68.7&#x02009;&#x000b1;&#x02009;9.8&#x000a0;&#x003bc;mol/L. Systolic brachial blood pressure (SBP) 119&#x02009;&#x000b1;&#x02009;10&#x000a0;mmHg, diastolic brachial blood pressure (DBP) 72&#x02009;&#x000b1;&#x02009;8&#x000a0;mmHg.</p></sec><sec id="Sec22"><title>Urine collection before the examination day</title><p>Twenty-four hours urine samples were collected prior to every examination day. Values are shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1. No differences were measured in UO, C<sub>H2O</sub>, u-AQP2, u-Na and u-K between the treatment periods.</p></sec><sec id="Sec23"><title><sup>51</sup>Cr-EDTA-clearance</title><p>During tolvaptan with NO inhibition, <sup>51</sup>Cr-EDTA-clearance did not change significantly. The relative changes in <sup>51</sup>Cr-EDTA-clearance were non-significant in the four treatment arms (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on the relative changes in GFR (&#x02206;<sup>51</sup> CrEDTA-clearance), urinary output (&#x02206; UO), free water clearance (&#x00394; C<sub>H2O</sub>), urinary aquaporin 2 excretion rate (&#x02206; AQP2), fractional excretion of sodium (&#x02206; FE<sub>Na</sub>) and urinary ENaC&#x003b3; excretion rate (&#x00394; ENaC&#x003b3;) in a randomized, placebo-controlled, double-blind, crossover, dose&#x02013;response study of 15 healthy subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Periods</th><th>Baseline</th><th colspan="2">L-NMMA</th><th colspan="2">Post infusion</th><th rowspan="2">p (GLM-within)</th></tr><tr><th/><th>0&#x02013;90&#x000a0;min</th><th>90&#x02013;120&#x000a0;min</th><th>120&#x02013;150&#x000a0;min</th><th>150&#x02013;180&#x000a0;min</th><th>180&#x02013;210&#x000a0;min</th></tr></thead><tbody><tr><td colspan="7">&#x00394; <sup>51</sup>Cr-EDTA-clearance (%)</td></tr><tr><td>Placebo</td><td>-</td><td>&#x02212;5&#x02009;&#x000b1;&#x02009;9</td><td>&#x02212;1&#x02009;&#x000b1;&#x02009;2</td><td>&#x02212;5&#x02009;&#x000b1;&#x02009;3</td><td>&#x02212;3&#x02009;&#x000b1;&#x02009;8</td><td rowspan="4">0.746</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>-</td><td>&#x02212;1&#x02009;&#x000b1;&#x02009;7</td><td>2&#x02009;&#x000b1;&#x02009;4</td><td>&#x02212;2&#x02009;&#x000b1;&#x02009;5</td><td>1&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>-</td><td>&#x02212;5&#x02009;&#x000b1;&#x02009;7</td><td>&#x02212;3&#x02009;&#x000b1;&#x02009;7</td><td>&#x02212;3&#x02009;&#x000b1;&#x02009;6</td><td>&#x02212;4&#x02009;&#x000b1;&#x02009;7</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>-</td><td>1&#x02009;&#x000b1;&#x02009;6</td><td>1&#x02009;&#x000b1;&#x02009;7</td><td>&#x02212;0.1&#x02009;&#x000b1;&#x02009;7</td><td>&#x02212;2&#x02009;&#x000b1;&#x02009;7</td></tr><tr><td>p (GLM between)</td><td/><td/><td>0.447</td><td/><td/><td/></tr><tr><td colspan="7">&#x00394; UO (%)</td></tr><tr><td>Placebo</td><td>-</td><td>&#x02212;49 (&#x02212;59;&#x02212;13)</td><td>&#x02212;41 (&#x02212;49;&#x02212;5)</td><td>&#x02212;26 (&#x02212;42;5)</td><td>&#x02212;6 (&#x02212;27;30)</td><td rowspan="4">&#x0003c;0.0001</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>-</td><td>&#x02212;46 (&#x02212;57;&#x02212;34)</td><td>&#x02212;48 (&#x02212;51;&#x02212;38)</td><td>&#x02212;45 (&#x02212;49;&#x02212;39)</td><td>&#x02212;40 (&#x02212;47;&#x02212;26)</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>-</td><td>&#x02212;40 (&#x02212;54;&#x02212;32)</td><td>&#x02212;42 (&#x02212;55;&#x02212;34)</td><td>&#x02212;47 (&#x02212;55;&#x02212;28)</td><td>&#x02212;39 (&#x02212;44;&#x02212;25)</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>-</td><td>&#x02212;31 (&#x02212;38;&#x02212;27)</td><td>&#x02212;42 (&#x02212;43;&#x02212;31)</td><td>&#x02212;32 (&#x02212;41;&#x02212;26)</td><td>&#x02212;31 (&#x02212;36;&#x02212;24)</td></tr><tr><td>p (GLM between)</td><td/><td/><td>0.002</td><td/><td/><td/></tr><tr><td>p (ANOVA)</td><td>-</td><td>0.217</td><td>0.078</td><td>0.001</td><td>&#x0003c;0.0001</td><td/></tr><tr><td colspan="7">&#x00394; C<sub>H2O</sub> (%)</td></tr><tr><td>Placebo</td><td>-</td><td>&#x02212;57 (&#x02212;78;&#x02212;25)</td><td>&#x02212;47 (&#x02212;63;0)</td><td>&#x02212;31 (&#x02212;50;14)</td><td>&#x02212;0.5 (&#x02212;31;37)</td><td rowspan="4">&#x0003c;0.0001</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>-</td><td>&#x02212;53 (&#x02212;66;&#x02212;41)</td><td>&#x02212;56 (&#x02212;60;&#x02212;39)</td><td>&#x02212;54 (&#x02212;66;&#x02212;47)</td><td>&#x02212;51 (&#x02212;59;&#x02212;46)</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>-</td><td>&#x02212;38 (&#x02212;65;&#x02212;33)</td><td>&#x02212;46 (&#x02212;66;&#x02212;38)</td><td>&#x02212;51 (&#x02212;63;&#x02212;35</td><td>&#x02212;42 (&#x02212;61;&#x02212;31)</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>-</td><td>&#x02212;35 (&#x02212;49;&#x02212;30)</td><td>&#x02212;47 (&#x02212;57;&#x02212;36)</td><td>&#x02212;33 (&#x02212;54;&#x02212;30)</td><td>&#x02212;31 (&#x02212;46;&#x02212;26)</td></tr><tr><td>p (GLM between)</td><td/><td/><td>0.004</td><td/><td/><td/></tr><tr><td>p (ANOVA)</td><td>-</td><td>0.156</td><td>0.130</td><td>0.011</td><td>0.002</td><td/></tr><tr><td colspan="7">&#x00394; AQP2 (%)</td></tr><tr><td>Placebo</td><td>-</td><td>&#x02212;19 (&#x02212;29;&#x02212;2)</td><td>&#x02212;21 (&#x02212;29;&#x02212;18)</td><td>&#x02212;21 (&#x02212;28;&#x02212;12)</td><td>&#x02212;13 (&#x02212;23;&#x02212;3)</td><td rowspan="4">0.233</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>-</td><td>&#x02212;18 (&#x02212;26;&#x02212;7)</td><td>&#x02212;13 (&#x02212;18;&#x02212;7)</td><td>&#x02212;9 (&#x02212;18;&#x02212;2)</td><td>&#x02212;4 (&#x02212;18;11)</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>-</td><td>&#x02212;14 (&#x02212;26;&#x02212;5)</td><td>&#x02212;19 (&#x02212;28;&#x02212;11)</td><td>&#x02212;12 (&#x02212;24;&#x02212;2)</td><td>&#x02212;4 (&#x02212;13;6)</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>-</td><td>&#x02212;9 (&#x02212;22;3)</td><td>&#x02212;13 (&#x02212;22;&#x02212;2)</td><td>&#x02212;13&#x02013;23;&#x02212;4) (</td><td>&#x02212;2 (&#x02212;11;6)</td></tr><tr><td>p (GLM between)</td><td/><td/><td>0.094</td><td/><td/><td/></tr><tr><td colspan="7">&#x00394;FE<sub>Na</sub> (%)</td></tr><tr><td>Placebo</td><td>-</td><td>&#x02212;25 (&#x02212;33;&#x02212;9)</td><td>&#x02212;33 (&#x02212;40;&#x02212;28)</td><td>&#x02212;12 (&#x02212;30;1)</td><td>4 (&#x02212;11;25)</td><td rowspan="4">0.433</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>-</td><td>&#x02212;14 (&#x02212;28;&#x02212;3)</td><td>&#x02212;17 (&#x02212;23;8)</td><td>17 (&#x02212;5;34)</td><td>46 (0;55)</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>-</td><td>&#x02212;15 (&#x02212;18;9)</td><td>&#x02212;10 (&#x02212;18;9)</td><td>13 (0;19)</td><td>44 (19;61)</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>-</td><td>&#x02212;12 (&#x02212;28;4)</td><td>&#x02212;9 (&#x02212;26;4)</td><td>3 (11;64)</td><td>45 (19;91)</td></tr><tr><td>p (GLM between)</td><td/><td/><td>0.014</td><td/><td/><td/></tr><tr><td>p (ANOVA)</td><td>-</td><td>0.207</td><td>0.009</td><td>0.014</td><td>0.021</td><td/></tr><tr><td colspan="7">&#x00394; ENaC<sub>&#x003b3;</sub> (%)</td></tr><tr><td>Placebo</td><td>-</td><td>&#x02212;11 (&#x02212;16;&#x02212;7)</td><td>&#x02212;8 (&#x02212;20;&#x02212;3)</td><td>&#x02212;11 (&#x02212;23;&#x02212;3)</td><td>2 (&#x02212;13;18)</td><td/></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>-</td><td>&#x02212;9 (&#x02212;21;&#x02212;2)</td><td>&#x02212;7 (&#x02212;15;22)</td><td>5 (&#x02212;8;13)</td><td>6 (&#x02212;7;&#x02212;21)</td><td/></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>-</td><td>&#x02212;3 (&#x02212;13;3)</td><td>&#x02212;5 (&#x02212;10;5)</td><td>3 (&#x02212;1; 13)</td><td>8 (&#x02212;8;19)</td><td/></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>-</td><td>&#x02212;13 (&#x02212;21;3)</td><td>&#x02212;5 (&#x02212;10;6)</td><td>&#x02212;2 (&#x02212;8;10)</td><td>13 (&#x02212;7;18)</td><td/></tr><tr><td>p (Friedman)</td><td>-</td><td>0.564</td><td>0.392</td><td>0.008</td><td>0.031</td><td/></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SD or medians with 25 <sup>th</sup> and 75 <sup>th</sup> percentiles in parentheses. General linear model (GLM) with repeated measures was performed for comparison within and between groups or Friedman test for comparison between groups. One-way ANOVA was used to test differences between tolvaptan 15, 30 and 45&#x000a0;mg vs placebo. Paired <italic>t</italic>-test was used for comparison between the three tolvaptan doses at baseline period (0&#x02013;90&#x000a0;min), L-NMMA period (90&#x02013;150&#x000a0;min) and post infusion period (150&#x02013;210&#x000a0;min); the significance levels are listed under the result section</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec24"><title>Urinary output and free water clearance</title><p>Absolute and relative values of UO and C<sub>H2O</sub> are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>-<xref rid="Fig1" ref-type="fig">c</xref> and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on GFR (<sup>51</sup> Cr-EDTA-clearance) (<bold>a</bold>), UO (<bold>b</bold>), C<sub>H2O</sub> (<bold>c</bold>) and u-AQP2 (<bold>d</bold>). Data are presented as mean&#x02009;&#x000b1;&#x02009;SEM. General linear model (GLM) with repeated measures was performed for comparison within and between groups. One-way ANOVA (*) was used to test differences between tolvaptan 15, 30 and 45&#x000a0;mg vs placebo. Paired <italic>t</italic>-test (&#x003b1;/&#x003b2;/&#x003b3;) was used for comparison of infusion period (90&#x02013;150&#x000a0;min) vs baseline period (0&#x02013;90&#x000a0;min) and post infusion period (150&#x02013;210&#x000a0;min) vs baseline period.<bold>&#x02020;</bold>
<italic>p</italic>&#x0003c;; 0.05; <bold>&#x02020;&#x02020;</bold>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; */<bold>&#x02020;&#x02020;&#x02020;</bold>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001. Paired <italic>t</italic>-test was used for comparison between the three tolvaptan doses at baseline period (0&#x02013;90&#x000a0;min), L-NMMA infusion period (90&#x02013;150&#x000a0;min) and post infusion period (150&#x02013;210&#x000a0;min); the significance levels are listed under the result section</p></caption><graphic xlink:href="12882_2017_501_Fig1_HTML" id="MO1"/></fig>
</p><p>During L-NMMA infusion 90&#x02013;120&#x000a0;min, UO decreased significantly during all treatments (placebo: 3.0&#x000a0;ml/min (49%); tolvaptan 15&#x000a0;mg: 4.8&#x000a0;ml/min (46%); tolvaptan 30&#x000a0;mg: 4.6&#x000a0;ml/min (40%); tolvaptan 45&#x000a0;mg: 3.6&#x000a0;ml/min (31%)). As during baseline, the absolute level of UO remained lower during placebo than tolvaptan, and no significant differences were measured between the different doses of tolvaptan. The relative changes from baseline to L-NMMA infusion were the same during both placebo and tolvaptan treatment. However, a tendency to a dose response effect was seen both in the absolute and relative measurements. During the post infusion period 180&#x02013;210&#x000a0;min, UO increased during placebo to the same level as during baseline, but remained reduced to the same levels during the three doses of tolvaptan (placebo: 0.7&#x000a0;ml/min (6%); tolvaptan 15&#x000a0;mg: 4.1&#x000a0;ml/min (40%); tolvaptan 30&#x000a0;mg: 4.6&#x000a0;ml/min (39%); tolvaptan 45&#x000a0;mg: 3.1&#x000a0;ml/min (31%)).</p><p>During L-NMMA infusion 90&#x02013;120&#x000a0;min, C<sub>H2O</sub> decreased during all treatments (placebo: 2.1&#x000a0;ml/min (57%); tolvaptan 15&#x000a0;mg: 4.3&#x000a0;ml/min (53%); tolvaptan 30&#x000a0;mg: 4.2&#x000a0;ml/min (38%); tolvaptan 45&#x000a0;mg: 3.3&#x000a0;ml/min (35%)). The absolute level of C<sub>H2O</sub> remained lower during placebo than tolvaptan treatment, and C<sub>H2O</sub> decreased significantly more after tolvaptan 15&#x000a0;mg compared to 30 and 45&#x000a0;mg (<italic>p</italic>&#x02009;=&#x02009;0.034 and 0.004 respectively). The relative changes from baseline to L-NMMA infusion did not deviate significantly between the four treatments, but a tendency to a dose response effect was measured with the lowest decrease in the highest tolvaptan dosis. During the post infusion period 180&#x02013;210&#x000a0;min, C<sub>H2O</sub> increased during placebo to the same level as during baseline, but remained reduced during tolvaptan treatment (placebo: 0.5&#x000a0;ml/min (0.5%); tolvaptan 15&#x000a0;mg: 4.2&#x000a0;ml/min (51%)); tolvaptan 30&#x000a0;mg: 4.2&#x000a0;ml/min (42%); tolvaptan 45&#x000a0;mg: 3.2&#x000a0;ml/min (31%)). The difference in C<sub>H2O</sub> between the three tolvaptan doses was non-significant but a tendency to a dose response effect was seen.</p></sec><sec id="Sec25"><title>Fractional excretion of sodium</title><p>Absolute and relative values of FE<sub>Na</sub> are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref> and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on FE<sub>Na</sub> (<bold>e</bold>) and u-ENaC&#x003b3; (<bold>f</bold>). Data are presented as mean&#x02009;&#x000b1;&#x02009;SEM. General linear model (GLM) with repeated measures was performed for comparison within and between groups. One-way ANOVA (*) was used to test differences between tolvaptan 15, 30 and 45&#x000a0;mg vs placebo. Paired <italic>t</italic>-test (&#x003b1;/&#x003b2;/&#x003b3;) was used for comparison of infusion period (90&#x02013;150&#x000a0;min) vs baseline period (0&#x02013;90&#x000a0;min) and post infusion period (150&#x02013;210&#x000a0;min) vs baseline period. <bold>&#x02020;</bold>
<italic>p</italic>&#x0003c;; 0.05; <bold>&#x02020;&#x02020;</bold>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; */<bold>&#x02020;&#x02020;&#x02020;</bold>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001. Paired <italic>t</italic>-test was used for comparison between the three tolvaptan doses at baseline period (0&#x02013;90&#x000a0;min), L-NMMA infusion period (90&#x02013;150&#x000a0;min) and post infusion period (150&#x02013;210&#x000a0;min); the significance levels are listed under the result section</p></caption><graphic xlink:href="12882_2017_501_Fig2_HTML" id="MO2"/></fig>
</p><p>During L-NMMA infusion 90&#x02013;120&#x000a0;min, FE<sub>Na</sub> decreased significantly after placebo and tolvaptan 15&#x000a0;mg (placebo: 0.37% (the relative decrease in percent: 25%); tolvaptan 15&#x000a0;mg: 0.20% (14%); tolvaptan 30&#x000a0;mg: 0.12% (15%); tolvaptan 45&#x000a0;mg: 0.14% (12%)). However, FE<sub>Na</sub> decreased to the same level as after tolvaptan 30 and 45&#x000a0;mg during the first 30&#x000a0;min of L-NMMA infusion period 90&#x02013;120&#x000a0;min. However, during the last LNMMA infusion period 120&#x02013;150&#x000a0;min, FE<sub>Na</sub> decreased to a significantly lesser extent after all tolvaptan doses compared with placebo (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). During the post infusion period 180&#x02013;210&#x000a0;min, FE<sub>Na</sub> increased after all treatments, but to a much higher level after tolvaptan (placebo: 0.04% (the increase in percent; 4%); tolvaptan 15&#x000a0;mg: 0.36% (46%); tolvaptan 30&#x000a0;mg:0.52% (44%); tolvaptan 45&#x000a0;mg: 0.42% (45%)). No dose response pattern was seen either in the absolute or relative measurements of FE<sub>Na</sub>.</p></sec><sec id="Sec26"><title>U-AQP2 and U-ENaC<sub>&#x003b3;</sub></title><p>During tolvaptan with NO-inhibition 90&#x02013;120&#x000a0;min, u-AQP2 decreased to the same level within all treatment arms. The same response was observed in the relative changes. During the post infusion period 180&#x02013;210&#x000a0;min, u-AQP2 remained reduced during placebo treatment, but had increased to baseline level during all tolvaptan doses. No dose response pattern was seen, in either the absolute or relative measurements of u-AQP2 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref> and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p>During tolvaptan with NO-inhibition 90&#x02013;120&#x000a0;min, u-ENaC<sub>&#x003b3;</sub> decreased significantly after placebo, but during tolvaptan treatment no significant differences existed between the placebo group and the three tolvaptan doses either in absolute or relative measurements (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref> and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). During the post infusion period 180&#x02013;210&#x000a0;min, u-ENaC<sub>&#x003b3;</sub> was unchanged compared to baseline measurement both during placebo and tolvaptan treatment. A significant difference was measured in the relative values with a dose response pattern and the highest increase during the highest tolvaptan dosis (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec27"><title>Plasma sodium and plasma osmolarity</title><p>At baseline, p-Na and p-osm were significantly higher and similar after tolvaptan 15, 30 and 45&#x000a0;mg compared to placebo and this response was sustained during tolvaptan with NO-inhibition (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2).</p></sec><sec id="Sec28"><title>Vasoactive hormones</title><p>During tolvaptan with NO-inhibition, none of the vasoactive hormones were affected a part from the sustained 3- fold increase in p-AVP after all three tolvaptan doses (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S3).</p></sec><sec id="Sec29"><title>Brachial blood pressure</title><p>During baseline conditions, SBP, DBP and pulse rate were the same within all treatments (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Table S4).</p><p>In response to tolvaptan with NO-inhibition, DBP increased after placebo, but remained constant after tolvaptan 15, 30 and 45&#x000a0;mg. Otherwise no differences were measured in SBP and pulse rate.</p></sec><sec id="Sec30"><title>Central blood pressure</title><p>At baseline, PWV, AI, CSBP and CDBP were identical after tolvaptan 15, 30 and 45&#x000a0;mg versus placebo. During tolvaptan with NO-inhibition, CSBP and CDBP increased equally after all treatments (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). PWV was not affected by L-NMMA infusion after placebo whereas a similar increase after tolvaptan 15, 30 and 45&#x000a0;mg was measured, but only to the same level observed after placebo. Tolvaptan 15 and 30&#x000a0;mg did not change AI. The value of AI was higher after tolvaptan 45&#x000a0;mg. However, no differences were measured between treatment groups.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on pulse wave velocity (PWV), augmentation index (AI), central diastolic and systolic blood pressure (CBDP and CSBP) in a randomized, placebo-controlled, double-blind, crossover, dose-response study of 15 healthy subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Prior to L-NMMA infusion (at 70&#x000a0;min)</th><th>During L-NMMA infusion (at 130&#x000a0;min)</th></tr></thead><tbody><tr><td colspan="3">PWV(m/s)</td></tr><tr><td>Placebo</td><td>5.2&#x02009;&#x000b1;&#x02009;0.5</td><td>5.4&#x02009;&#x000b1;&#x02009;0.5</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>5.0&#x02009;&#x000b1;&#x02009;0.5</td><td>5.4&#x02009;&#x000b1;&#x02009;0.6<sup>**</sup>
</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>5.2&#x02009;&#x000b1;&#x02009;0.6</td><td>5.5&#x02009;&#x000b1;&#x02009;0.6 <sup>**</sup>
</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>5.2&#x02009;&#x000b1;&#x02009;0.3</td><td>5.5&#x02009;&#x000b1;&#x02009;0.4<sup>**</sup>
</td></tr><tr><td>p (ANOVA)</td><td>0.518</td><td>0.851</td></tr><tr><td colspan="3">AI</td></tr><tr><td>Placebo</td><td>&#x02212;0.7&#x02009;&#x000b1;&#x02009;13.8</td><td>0.1&#x02009;&#x000b1;&#x02009;15.1</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>&#x02212;1.5&#x02009;&#x000b1;&#x02009;12.5</td><td>&#x02212;1.2&#x02009;&#x000b1;&#x02009;17.3</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>&#x02212;0.4&#x02009;&#x000b1;&#x02009;11.8</td><td>2.5&#x02009;&#x000b1;&#x02009;17.8</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>&#x02212;3.3&#x02009;&#x000b1;&#x02009;15.8</td><td>1.6&#x02009;&#x000b1;&#x02009;12.0<sup>*</sup>
</td></tr><tr><td>p (ANOVA)</td><td>0.968</td><td>0.961</td></tr><tr><td colspan="3">CSBP</td></tr><tr><td>Placebo</td><td>97&#x02009;&#x000b1;&#x02009;9</td><td>100&#x02009;&#x000b1;&#x02009;8<sup>**</sup>
</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>97&#x02009;&#x000b1;&#x02009;9</td><td>101&#x02009;&#x000b1;&#x02009;10<sup>*</sup>
</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>96&#x02009;&#x000b1;&#x02009;9</td><td>102&#x02009;&#x000b1;&#x02009;9<sup>**</sup>
</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>96&#x02009;&#x000b1;&#x02009;8</td><td>102&#x02009;&#x000b1;&#x02009;6<sup>**</sup>
</td></tr><tr><td>p (ANOVA)</td><td>0.989</td><td>0.952</td></tr><tr><td colspan="3">CDBP</td></tr><tr><td>Placebo</td><td>63&#x02009;&#x000b1;&#x02009;7</td><td>68&#x02009;&#x000b1;&#x02009;6<sup>***</sup>
</td></tr><tr><td>Tolvaptan 15&#x000a0;mg</td><td>63&#x02009;&#x000b1;&#x02009;7</td><td>68&#x02009;&#x000b1;&#x02009;9<sup>**</sup>
</td></tr><tr><td>Tolvaptan 30&#x000a0;mg</td><td>61&#x02009;&#x000b1;&#x02009;6</td><td>68&#x02009;&#x000b1;&#x02009;7<sup>***</sup>
</td></tr><tr><td>Tolvaptan 45&#x000a0;mg</td><td>62&#x02009;&#x000b1;&#x02009;5</td><td>68&#x02009;&#x000b1;&#x02009;6<sup>**</sup>
</td></tr><tr><td>p (ANOVA)</td><td>0.936</td><td>0.998</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SD. One-way ANOVA was performed to test differences between treatments groups. Paired <italic>t</italic>-test (*) was used for comparison of data during L-NMMA infusion vs prior to L-NMMA infusion</p><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec31"><title>Water and sodium excretion, BP and vasoactive hormones during baseline</title><p>
<sup>51</sup>Cr-EDTA-clearance was similar after placebo and tolvaptan (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>).</p><p>UO was significantly lower during placebo than tolvaptan treatment (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). UO was lower after tolvaptan 15&#x000a0;mg compared with tolvaptan 30&#x000a0;mg (<italic>p</italic>&#x02009;=&#x02009;0.005), while no difference was measured between tolvaptan 30 and 45&#x000a0;mg. C<sub>H2O</sub> was significantly lower during placebo than tolvaptan treatment. C<sub>H2O</sub> increased significantly more after tolvaptan 30&#x000a0;mg compared with 15&#x000a0;mg (<italic>p</italic>&#x02009;=&#x02009;0.004), but no further increase was measured after tolvaptan 45&#x000a0;mg (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>).</p><p>FE<sub>Na</sub> was the same after all treatments. No significant difference was measured between the three tolvaptan doses (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>).</p><p>U-AQP2 was similar after tolvaptan 15, 30 and 45&#x000a0;mg or placebo (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). U-ENaC<sub>&#x003b3;</sub> was significantly higher after placebo than after tolvaptan treatment, and a dose-response effect was measured with the lowest level of u-ENaC&#x003b3; during the highest tolvaptan dosis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref>).</p><p>PRC, p-ANGII and p-Aldo were the same after tolvaptan 15, 30 and 45&#x000a0;mg compared with placebo (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S3). A highly significant and non-dose dependent 3-fold increase in p-AVP was measured after all three doses of tolvaptan (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). No difference was measured between the three tolvaptan doses (<italic>p</italic>&#x02009;=&#x02009;0.645).<fig id="Fig3"><label>Fig. 3</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg on p-AVP at baseline, during and after NO-inhibition. Data are depicted as mean&#x02009;&#x000b1;&#x02009;SEM. Friedman test was used for comparison between treatment groups prior to L-NMMA infusion, at the end of L-NMMA infusion and 1&#x000a0;h after the end of L-NMMA infusion</p></caption><graphic xlink:href="12882_2017_501_Fig3_HTML" id="MO3"/></fig>
</p></sec></sec><sec id="Sec32"><title>Discussion</title><p>In the present dose-response study, we investigated short-term effects of tolvaptan on renal tubular function, vasoactive hormones and systemic hemodynamics during basal conditions and during tolvaptan with NO-inhibition in healthy subject. The present study is a continuation and expansion of a previous randomized, double-blinded, placebo-controlled crossover, single-dose study conducted by our laboratory [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>At baseline, tolvaptan increased renal water excretion dose-dependently up to 30&#x000a0;mg, without affecting sodium excretion. During L-NMMA infusion, tolvaptan decreased water excretion dose-dependently, whereas sodium excretion decreased independently of the dose. In the post infusion period, water excretion remained reduced during all tolvaptan doses, but increased during placebo. Tolvaptan increased sodium excretion to a higher level.</p><p>Recent dose-response trials have shown that oral administration of tolvaptan 30&#x000a0;mg led to a fast increase in the effective concentration in plasma. This increase was however followed by a fast decline due to tolvaptan&#x02019;s short half-life of approximately 6&#x02013;8 h [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The absolute bioavailability of tolvaptan is approximately 56% and a plasma concentration peak (300&#x000a0;ng/ml) is obtained 2&#x02013;4 h post-dosing. Based on the pharmacological profile of tolvaptan, we think that oral administration of tolvaptan at 8:00&#x000a0;AM (approximately 3&#x000a0;h prior to L-NMMA infusion) was the optimal time. The results from our previous study of tolvaptan 15&#x000a0;mg confirmed a significant increase in OU and C<sub>H2O</sub> that was measurable within approximately 2-3 h post-dose [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>In the present trial, tolvaptan increased UO and C<sub>H2O</sub> dose-dependently when tolvaptan dose was ascended from 15 to 30&#x000a0;mg during baseline, but no further increase was measured after tolvaptan 45&#x000a0;mg. This observation does not exclude that a much higher dose might further increase renal water excretion. In addition, a longer observation time might be needed to obtain a further increase in UO and C<sub>H2O.</sub> Several of the participants reported significant and frequent diuresis after they have left our facilities. In previous clinical studies, using much higher tolvaptan doses ranging from 60 to 480&#x000a0;mg, tolvaptan increased C<sub>H2O</sub> in a dose-independent relationship and UO in a dose-dependent relationship [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In these studies, UO and C<sub>H2O</sub> were collected and measured over a longer observation period around 24-h and up to 144&#x000a0;h post-dose.</p><p>During L-NMMA infusion, UO and C<sub>H2O</sub> declined in all treatment arms, confirming the well-known antidiuretic effect by blocking the diuretic action of NO. However, UO remained approximately 30&#x02013;50% higher after tolvaptan, and p-AVP also remained at the high level and unchanged from baseline. The degree of decline in C<sub>H2O</sub> tended to be dependent of the tolvaptan dose, as C<sub>H2O</sub> fell less after tolvaptan 30 and 45&#x000a0;mg than after 15&#x000a0;mg. In the post infusion period, UO and C<sub>H2O</sub> remained reduced to the same levels during the three tolvaptan doses. This may reflect an interaction between the V2 receptor system and the NO system, expressed as a higher level of water excretion after tolvaptan. Thus, tolvaptan partly antagonized the antidiuretic action of L-NMMA. This is in agreement with NO having a stimulating effect on renal water excretion in the renal principal cells that seemed to be partly AVP-dependent. Our results are, however, not in agreement with the findings observed in our previous clinical study of tolvaptan 15&#x000a0;mg, in which we showed that tolvaptan potentiated the antidiuretic action of L-NMMA [<xref ref-type="bibr" rid="CR12">12</xref>]. A possible explanation of this discrepancy could be that tolvaptan was given 2&#x000a0;h earlier, at 6:00&#x000a0;AM versus 8:00&#x000a0;AM in the present study. Therefore, tolvaptan exerted its effect over a longer period before the L-NMMA intervention.</p><p>Tolvaptan prevented fusion of cytoplasmic vesicles containing AQP2 to the apical membrane as response to activation of V2 receptors by AVP [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. As a result, the activation rate of AQP2 is declined. This response is biochemically reflected as a decline in the excretion of AQP2 into the urine [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Increased u-AQP2 reflects increased water transport from the tubular lumen to the intracellular space via the aquaporin2 water channels, located in the principal cells in the distal part of the nephron [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Surprisingly, u-AQP2 did not change after oral administration of tolvaptan, not even in response to the highest dose of tolvaptan. We measured a similar response in our previous study of tolvaptan 15&#x000a0;mg [<xref ref-type="bibr" rid="CR12">12</xref>]. Most likely, this could be explained by the measured 3-fold increase in plasma AVP. The increase in AVP exerts a competitive inhibition on the V2 receptor, thereby interfering with tolvaptan&#x02019;s binding to the V2 receptor. Alternatively, the baseline period could be too short to reflect the expected decline in u-AQP2 after oral administration of tolvaptan.</p><p>At baseline, FE<sub>Na</sub> was identical after all treatments, whereas u-ENaC<sub>&#x003b3;</sub> decreased dose-independently after tolvaptan. Several experimental and clinical trials have appointed the AVP-V2R-ENaC<sub>&#x003b3;</sub> axis as an essential physiological mechanism in the final regulation of sodium excretion [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Our findings are in agreement with these results, as we measured a reduced and similar baseline level of u-ENaC<sub>&#x003b3;</sub> after all tolvaptan doses. There was a clear tendency to a dose-response pattern with the lowest u-ENaC<sub>&#x003b3;</sub> at the highest dosis of tolvaptan. However, we did not measure an increase in FE<sub>Na</sub>. This observation could be explained by the primarily aquaretic effect of selective V2R antagonism that is shown to be approximately 4 times the natriuretic effect [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>During tolvaptan with NO-inhibition, FE<sub>Na</sub> declined less pronouncedly after tolvaptan and the degree of the decline was not dependent of tolvaptan dosis. The sodium transport via the epithelial sodium channels is supposed to be reflected by the level of urinary excretion of a protein fraction from the channels (u-ENaC<sub>&#x003b3;</sub>) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. U-ENaC<sub>&#x003b3;</sub> decreased after placebo and remained unchanged, but at a lower level after tolvaptan treatment. In the post infusion period, FE<sub>Na</sub> increased more and dose-independently after tolvaptan. U-ENaC<sub>&#x003b3;</sub> also increased, but with a dose response relationship and the highest increase was measured during tolvaptan 45&#x000a0;mg. This observation was different from our previous single-dose study of tolvaptan, where u- ENaC<sub>&#x003b3;</sub> increased after NO-inhibition and remained higher in the post infusion period. This in turn, could also be attributed to the 2&#x000a0;h longer reaction time for tolvaptan in the first study [<xref ref-type="bibr" rid="CR12">12</xref>], during which the effective concentration in plasma may have been lowered owing tolvaptan&#x02019;s relatively short half-life. Therefore, a lesser effect remained when L-NMMA was administered. Thus, tolvaptan inhibited the antinatriuretic effect of systemic NO-inhibition partially via an AVP-dependent pathway, and the degree of inhibition followed a dose-independent relationship.</p><p>We measured a significant and three-fold non-dose-dependent increase in p-AVP after all three tolvaptan doses. Endogenous AVP release appeared to reach a plateau at a tolvaptan dose of 15&#x000a0;mg. This compensatory release of AVP due to treatment with V2 receptor antagonist is well documented [<xref ref-type="bibr" rid="CR26">26</xref>]. However, the absence of a dose-response pattern in vasopressin has previously been demonstrated during tolvaptan treatment. Also, this response in plasma AVP was not affected by inhibition of systemic NO after all treatments. Thus, NO did not seem to play a role in the AVP releasing mechanism. Our results are in agreement with previous studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Brachial and central BP remained unaffected even with an approximate 3-fold increase in p-AVP after tolvaptan 15, 30 amd 45&#x000a0;mg. Applanation tonometry was also performed under standardized conditions. The method is described and evaluated elsewhere [<xref ref-type="bibr" rid="CR39">39</xref>]. Inhibition of systemic NO synthesis caused an increase in cBP, but to the same level within all treatments. In addition to its aquaretic effect, tolvaptan is believed to exert a pressor effect via the V1a receptors, localized in the vascular smooth muscle cells, as a consequence of compensatory increased endogenous AVP release. In turn, AVP may activate the V1a receptors at high plasma levels [<xref ref-type="bibr" rid="CR6">6</xref>]. However, we demonstrated that an increase in tolvaptan dose from 15 to 45&#x000a0;mg had no effect on bBP and cBP. This is in good agreement with the fact that we did not measure changes in P-AngII, PRC or P-Aldo after any of the three tolvaptan doses. In other words, we could not reject the null hypothesis, saying that tolvaptan would not change blood pressure using different doses of tolvaptan.</p><p>During baseline conditions, we measured a non-dose dependent increase in p-Na and p-osm after tolvaptan. Plasma sodium and p-osm remained 141&#x000a0;mmol/L and 288 mosm/kg respectively, even after tolvaptan 45&#x000a0;mg. Most likely, the response in p-Na and p-osm must be due to increased renal water excretion and consequently decline in the extracellular volume. V2 receptor antagonism has previously been shown to increase p-Na and p-osm in a non-dose-response manner [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The abovementioned parameters were not affected by NO inhibition. The results are in agreement with a previous clinical study reported by our laboratory [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec33"><title>Strengths and limitations</title><p>The major strengths of our study are a combination of the study design as randomized, placebo-controlled, double-blinded, crossover trial, and the standardized diet and fluid intake to avoid any confounding of the results. It might be considered as a weakness of the study that the assumption of abrogated systemic NO synthesis was exclusively based on the measurement of the response in <sup>51</sup>Cr-EDTA-clearance, C<sub>H2O</sub>, UO, u-AQP<sub>2</sub>, FE<sub>Na</sub> and mean arterial blood pressure. A measurement of nitrate or nitrite in plasma or urine could have documented the NO inhibition directly, but this method is difficult, and according to our experience not as reliable as the methods used in the present study.</p><p>Emerging data indicate that the regulated protein fractions of AQP2 and ENaC<sub>&#x003b3;</sub> are excreted as urinary exosomes. These fraction were not isolated and analyzed in the present study.</p><p>We cannot exclude possible gender differences in the parameters studied due to female predominance.</p></sec><sec id="Sec34"><title>Conclusions</title><p>During baseline conditions, tolvaptan increased renal water excretion dose-dependently, whereas tubular handling of sodium was unchanged. During tolvaptan with NO-inhibition, renal water excretion was reduced dose-dependently, and renal sodium excretion non-dose-dependently partly via an AVP-dependent mechanism. The lack of decrease in u-AQP2 by tolvaptan could be explained by a counteracting effect of elevated vasopressin in plasma.</p></sec></body><back><app-group><app id="App1"><sec id="Sec35"><title>Additional files</title><p>
<media position="anchor" xlink:href="12882_2017_501_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Urine output, free water clearance (C<sub>H2O</sub>), urinary AQP2 excretion per minute (u-AQP2), urinary sodium excretion (u-Na) and urinary potassium excretion (u-K) during 24-h urine collection in a randomised, placebo-controlled, double-blind, crossover, dose-response study of 15 healthy subjects. Values are means with&#x02009;&#x000b1;&#x02009;SD. One-way ANOVA was used for comparison between groups. (PDF 9&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12882_2017_501_MOESM2_ESM.pdf" id="MOESM2"><label>Additional file 2: Table S2.</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on plasma concentration of sodium and plasma osmolality in a randomized, placebo-controlled, double-blind, crossover, dose-response study of 15 healthy subjects. Data are presented as mean&#x02009;&#x000b1;&#x02009;SD. General linear model (GLM) with repeated measurements was performed for comparison within and between groups. One-way ANOVA was used to test differences between tolvaptan 15, 30 and 45&#x000a0;mg vs placebo. Paired <italic>t</italic>-test was performed for comparison of infusion period (90&#x02013;150&#x000a0;min) vs baseline period (0&#x02013;90&#x000a0;min), and post infusion period (150&#x02013;210&#x000a0;min) vs baseline period. (PDF 84&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12882_2017_501_MOESM3_ESM.pdf" id="MOESM3"><label>Additional file 3: Table S3.</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on plasma concentrations of renin (PRC), angiotensin II (P-AngII) and aldosterone (P-aldo) in a randomized, placebo-controlled, double-blind, crossover, dose-response study of 15 healthy subjects. Data are presented as mean&#x02009;&#x000b1;&#x02009;SD. General linear model (GLM) with repeated measures was performed for comparison within and between groups. Paired <italic>t</italic>-test was used for comparison between L-NMMA infusion period (at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and at baseline vs post infusion period (1&#x000a0;h after L-NMMA infusion period) vs baseline period. One-way ANOVA was performed to test differences between treatment groups. (PDF 14&#x000a0;kb)</p></caption></media>
<media position="anchor" xlink:href="12882_2017_501_MOESM4_ESM.pdf" id="MOESM4"><label>Additional file 4: Table S4.</label><caption><p>Effect of tolvaptan 15, 30 and 45&#x000a0;mg at baseline, during and after NO-inhibition on brachial systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate in a randomized, placebo-controlled, double-blind, crossover, dose-response study of 15 healthy subjects. Data are presented as mean&#x02009;&#x000b1;&#x02009;SD. General linear model (GLM) with repeated measures was performed for comparison within and between treatment groups. Paired <italic>t</italic>-test was used for comparison of infusion period (at the beginning of LNMMA infusion period/at the end of LNMMA infusion period) vs baseline (prior to LNMMA infusion period) and LNMMA infusion period vs post infusion period (30&#x000a0;min after the end of LMMMA infusion period/60&#x000a0;min after the end of LNMMA infusion period). <sup>*</sup>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. One-way ANOVA was performed to test differences between treatment groups. (PDF 356&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AI</term><def><p>Augmentation index</p></def></def-item><def-item><term>bBP</term><def><p>brachial blood pressure</p></def></def-item><def-item><term>cBP</term><def><p>central blood pressure</p></def></def-item><def-item><term>C<sub>H2O</sub></term><def><p>Free water clearance</p></def></def-item><def-item><term>EMA</term><def><p>European Medicines Agency.</p></def></def-item><def-item><term>FE<sub>Na</sub></term><def><p>Fractional excretion of sodium</p></def></def-item><def-item><term>GFR (<sup>51</sup>Cr-EDTA-clearance)</term><def><p>Glomerular filtration rate</p></def></def-item><def-item><term>L-NMMA</term><def><p>L-NG-monomethyl-arginine</p></def></def-item><def-item><term>NO</term><def><p>Nitric Oxide</p></def></def-item><def-item><term>p-Aldo</term><def><p>plasma aldosterone</p></def></def-item><def-item><term>p-AngII</term><def><p>plasma angiotensinII</p></def></def-item><def-item><term>p-AVP</term><def><p>plasma vasopressin</p></def></def-item><def-item><term>PRC</term><def><p>Plasma concentrations of rennin</p></def></def-item><def-item><term>PW</term><def><p>Pulse wave velocity</p></def></def-item><def-item><term>u-AQP2</term><def><p>urinary aquaporin-2 channels</p></def></def-item><def-item><term>u-ENaC&#x003b3;</term><def><p>urinary epithelial sodium channels</p></def></def-item><def-item><term>UO</term><def><p>Urine output</p></def></def-item></def-list></glossary><ack><title>Acknowledgement</title><p>We thank our laboratory technicians, including Anne Mette Ravn, Henriette Vorup Simonsen and Kirsten Nyggard for their skillful assistance. We thank Otsuka for a research grant to the study.</p><sec id="FPar1"><title>Funding</title><p>The study was supported by grants from The Research Foundation of Central Denmark Region.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets used/or analyzed during the current study available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>SAT participated in the coordination of the study, recruitment of subjects and performed statistical analysis. SAT and JBR performed the experiments. EBP conceived of the study, participated in the design of the study and was responsible for the laboratory analyses. SAT, JBR, FHM, JNB and EBP wrote and edited the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>This study was approved by The Central Denmark Region Committees on Health Research Ethics (Clinical Trial no: NCT02078973). The study was conducted in conformity with the principles of the declaration of Helsinki. Written informed consent was obtained from all subjects.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>F</given-names></name><name><surname>Guglin</surname><given-names>M</given-names></name><name><surname>Vaitkevicius</surname><given-names>P</given-names></name><name><surname>Ghali</surname><given-names>JK</given-names></name></person-group><article-title>Therapeutic potential of vasopressin receptor antagonists</article-title><source>Drugs</source><year>2007</year><volume>67</volume><fpage>847</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.2165/00003495-200767060-00002</pub-id><pub-id pub-id-type="pmid">17428103</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrier</surname><given-names>RW</given-names></name><name><surname>Gross</surname><given-names>P</given-names></name><name><surname>Gheorghiade</surname><given-names>M</given-names></name><name><surname>Berl</surname><given-names>T</given-names></name><name><surname>Verbalis</surname><given-names>JG</given-names></name><name><surname>Czerwiec</surname><given-names>FS</given-names></name><name><surname>Orlandi</surname><given-names>C</given-names></name></person-group><article-title>Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia</article-title><source>NEnglJMed</source><year>2006</year><volume>355</volume><fpage>2099</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa065181</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbalis</surname><given-names>JG</given-names></name><name><surname>Goldsmith</surname><given-names>SR</given-names></name><name><surname>Greenberg</surname><given-names>A</given-names></name><name><surname>Schrier</surname><given-names>RW</given-names></name><name><surname>Sterns</surname><given-names>RH</given-names></name></person-group><article-title>Hyponatremia treatment guidelines 2007: expert panel recommendations</article-title><source>Am J Med</source><year>2007</year><volume>120</volume><fpage>S1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2007.09.001</pub-id><pub-id pub-id-type="pmid">17981159</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loffing</surname><given-names>J</given-names></name><name><surname>Korbmacher</surname><given-names>C</given-names></name></person-group><article-title>Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC)</article-title><source>Pflugers Arch</source><year>2009</year><volume>458</volume><fpage>111</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s00424-009-0656-0</pub-id><pub-id pub-id-type="pmid">19277701</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Kwon</surname><given-names>TH</given-names></name><name><surname>Christensen</surname><given-names>BM</given-names></name><name><surname>Promeneur</surname><given-names>D</given-names></name><name><surname>Frokiaer</surname><given-names>J</given-names></name><name><surname>Marples</surname><given-names>D</given-names></name></person-group><article-title>Physiology and pathophysiology of renal aquaporins</article-title><source>J Am Soc Nephrol</source><year>1999</year><volume>10</volume><fpage>647</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">10073616</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perucca</surname><given-names>J</given-names></name><name><surname>Bichet</surname><given-names>DG</given-names></name><name><surname>Bardoux</surname><given-names>P</given-names></name><name><surname>Bouby</surname><given-names>N</given-names></name><name><surname>Bankir</surname><given-names>L</given-names></name></person-group><article-title>Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><issue>9</issue><fpage>1721</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008010021</pub-id><pub-id pub-id-type="pmid">18596120</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Nejsum</surname><given-names>LN</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kwon</surname><given-names>TH</given-names></name><name><surname>Jonassen</surname><given-names>TE</given-names></name><name><surname>Knepper</surname><given-names>MA</given-names></name><name><surname>Thomsen</surname><given-names>K</given-names></name><name><surname>Frokiaer</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name></person-group><article-title>Biphasic effects of ANP infusion in conscious, euvolumic rats: roles of AQP2 and ENaC trafficking</article-title><source>Am J Physiol Renal Physiol</source><year>2006</year><volume>290</volume><fpage>F530</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00070.2005</pub-id><pub-id pub-id-type="pmid">16174867</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouley</surname><given-names>R</given-names></name><name><surname>Breton</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>McLaughlin</surname><given-names>M</given-names></name><name><surname>Nsumu</surname><given-names>NN</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Ausiello</surname><given-names>DA</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name></person-group><article-title>Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells</article-title><source>J Clin Invest</source><year>2000</year><volume>106</volume><fpage>1115</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1172/JCI9594</pub-id><pub-id pub-id-type="pmid">11067864</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klokkers</surname><given-names>J</given-names></name><name><surname>Langehanenberg</surname><given-names>P</given-names></name><name><surname>Kemper</surname><given-names>B</given-names></name><name><surname>Kosmeier</surname><given-names>S</given-names></name><name><surname>von Bally</surname><given-names>G</given-names></name><name><surname>Riethmuller</surname><given-names>C</given-names></name><name><surname>Wunder</surname><given-names>F</given-names></name><name><surname>Sindic</surname><given-names>A</given-names></name><name><surname>Pavenstadt</surname><given-names>H</given-names></name><name><surname>Schlatter</surname><given-names>E</given-names></name><name><surname>Edemir</surname><given-names>B</given-names></name></person-group><article-title>Atrial natriuretic peptide and nitric oxide signaling antagonizes vasopressin-mediated water permeability in inner medullary collecting duct cells</article-title><source>AmJPhysiol Renal Physiol</source><year>2009</year><volume>297</volume><fpage>F693</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00136.2009</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>C</given-names></name></person-group><article-title>Role of nitric oxide in the control of renin secretion</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><fpage>F849</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9843901</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>PA</given-names></name><name><surname>Garvin</surname><given-names>JL</given-names></name></person-group><article-title>Role of nitric oxide in the regulation of nephron transport</article-title><source>Am J Physiol Renal Physiol</source><year>2002</year><volume>282</volume><fpage>F777</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00334.2001</pub-id><pub-id pub-id-type="pmid">11934686</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al</surname><given-names>TS</given-names></name><name><surname>Mose</surname><given-names>FH</given-names></name><name><surname>Jensen</surname><given-names>JM</given-names></name><name><surname>Bech</surname><given-names>JN</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects</article-title><source>BMC Nephrol</source><year>2014</year><volume>15</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-15-100</pub-id><pub-id pub-id-type="pmid">24965902</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2011.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baylis</surname><given-names>C</given-names></name></person-group><article-title>Nitric oxide deficiency in chronic kidney disease</article-title><source>Am J Physiol Renal Physiol</source><year>2008</year><volume>294</volume><fpage>F1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00424.2007</pub-id><pub-id pub-id-type="pmid">17928410</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>T</given-names></name><name><surname>Mose</surname><given-names>FH</given-names></name><name><surname>Bech</surname><given-names>JN</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Effect of nitric oxide inhibition on blood pressure and renal sodium handling: a dose-response study in healthy man</article-title><source>Clin Exp Hypertens</source><year>2012</year><volume>34</volume><issue>8</issue><fpage>567</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3109/10641963.2012.681727</pub-id><pub-id pub-id-type="pmid">22559218</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Meininger</surname><given-names>CJ</given-names></name></person-group><article-title>Nitric oxide and vascular insulin resistance</article-title><source>Biofactors</source><year>2009</year><volume>35</volume><fpage>21</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/biof.3</pub-id><pub-id pub-id-type="pmid">19319842</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>Arici</surname><given-names>M</given-names></name><name><surname>Benzing</surname><given-names>T</given-names></name><etal/></person-group><article-title>Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTAWorking Groups on Inherited Kidney Disorders and European Renal Best Practice</article-title><source>Nephrol Dial Transplant</source><year>2016</year><volume>31</volume><fpage>337</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv456</pub-id><pub-id pub-id-type="pmid">26908832</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashihara</surname><given-names>E</given-names></name><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Chapman</surname><given-names>AB</given-names></name><name><surname>Grantham</surname><given-names>JJ</given-names></name><name><surname>Bae</surname><given-names>K</given-names></name><name><surname>Watnick</surname><given-names>TJ</given-names></name><name><surname>Horie</surname><given-names>S</given-names></name><name><surname>Nutahara</surname><given-names>K</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>Krasa</surname><given-names>HB</given-names></name><name><surname>Czerwiec</surname><given-names>FS</given-names></name></person-group><article-title>Tolvaptan in autosomal dominant polycystic kidney disease: three years&#x02019; experience</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><fpage>2499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.2215/CJN.03530411</pub-id><pub-id pub-id-type="pmid">21903984</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irazabal</surname><given-names>MV</given-names></name><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Hogan</surname><given-names>MC</given-names></name><name><surname>Glockner</surname><given-names>J</given-names></name><name><surname>King</surname><given-names>BF</given-names></name><name><surname>Ofstie</surname><given-names>TG</given-names></name><name><surname>Krasa</surname><given-names>HB</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>Czerwiec</surname><given-names>FS</given-names></name></person-group><article-title>Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease</article-title><source>Kidney Int</source><year>2011</year><volume>80</volume><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.119</pub-id><pub-id pub-id-type="pmid">21544064</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Chapman</surname><given-names>AB</given-names></name><name><surname>Devuyst</surname><given-names>O</given-names></name><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>Grantham</surname><given-names>JJ</given-names></name><name><surname>Higashihara</surname><given-names>E</given-names></name><name><surname>Perrone</surname><given-names>RD</given-names></name><name><surname>Krasa</surname><given-names>HB</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>Czerwiec</surname><given-names>FS</given-names></name></person-group><article-title>Tolvaptan in patients with autosomal dominant polycystic kidney disease</article-title><source>NEnglJMed</source><year>2012</year><volume>367</volume><fpage>2407</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1205511</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Meijer</surname><given-names>E</given-names></name><name><surname>Bae</surname><given-names>KT</given-names></name><name><surname>Chapman</surname><given-names>AB</given-names></name><name><surname>Devuyst</surname><given-names>O</given-names></name><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>Grantham</surname><given-names>JJ</given-names></name><name><surname>Higashihara</surname><given-names>E</given-names></name><name><surname>Perrone</surname><given-names>RD</given-names></name><name><surname>Krasa</surname><given-names>HB</given-names></name><name><surname>Ouyang</surname><given-names>JJ</given-names></name><name><surname>Czerwiec</surname><given-names>FS</given-names></name></person-group><article-title>Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3&#x02013;4 Study</article-title><source>Am J Kidney Dis</source><year>2011</year><volume>57</volume><fpage>692</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2010.11.029</pub-id><pub-id pub-id-type="pmid">21333426</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berl</surname><given-names>T</given-names></name><name><surname>Quittnat-Pelletier</surname><given-names>F</given-names></name><name><surname>Verbalis</surname><given-names>JG</given-names></name><name><surname>Schrier</surname><given-names>RW</given-names></name><name><surname>Bichet</surname><given-names>DG</given-names></name><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>Czerwiec</surname><given-names>FS</given-names></name></person-group><article-title>Oral tolvaptan is safe and effective in chronic hyponatremia</article-title><source>J Am Soc Nephrol</source><year>2010</year><volume>21</volume><fpage>705</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1681/ASN.2009080857</pub-id><pub-id pub-id-type="pmid">20185637</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasta</surname><given-names>JF</given-names></name><name><surname>Chiong</surname><given-names>JR</given-names></name><name><surname>Christian</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>K</given-names></name><name><surname>Lingohr-Smith</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Cassidy</surname><given-names>IB</given-names></name></person-group><article-title>Update on tolvaptan for the treatment of hyponatremia</article-title><source>Expert Rev Pharmacoecon Outcomes Res</source><year>2012</year><volume>12</volume><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1586/erp.12.30</pub-id><pub-id pub-id-type="pmid">22971027</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhassan</surname><given-names>EA</given-names></name><name><surname>Schrier</surname><given-names>RW</given-names></name></person-group><article-title>Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists</article-title><source>Curr Opin Nephrol Hypertens</source><year>2011</year><volume>20</volume><fpage>161</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/MNH.0b013e3283436f14</pub-id><pub-id pub-id-type="pmid">21252664</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellison</surname><given-names>DH</given-names></name><name><surname>Berl</surname><given-names>T</given-names></name></person-group><article-title>Clinical practice. The syndrome of inappropriate antidiuresis</article-title><source>NEnglJMed</source><year>2007</year><volume>356</volume><fpage>2064</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp066837</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>GL</given-names></name></person-group><article-title>Vaptans for the treatment of hyponatremia</article-title><source>Nat Rev Endocrinol</source><year>2011</year><volume>7</volume><fpage>151</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2010.229</pub-id><pub-id pub-id-type="pmid">21283124</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spasovski</surname><given-names>G</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>Allolio</surname><given-names>B</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Ball</surname><given-names>S</given-names></name><name><surname>Bichet</surname><given-names>D</given-names></name><name><surname>Decaux</surname><given-names>G</given-names></name><name><surname>Fenske</surname><given-names>W</given-names></name><name><surname>Hoorn</surname><given-names>EJ</given-names></name><name><surname>Ichai</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical practice guideline on diagnosis and treatment of hyponatraemia</article-title><source>Nephrol Dial Transplant</source><year>2014</year><volume>29</volume><issue>Suppl 2</issue><fpage>i1</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfu040</pub-id><pub-id pub-id-type="pmid">24569496</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graffe</surname><given-names>CC</given-names></name><name><surname>Bech</surname><given-names>JN</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Effect of high and low sodium intake on urinary aquaporin-2 excretion in healthy humans</article-title><source>AM J Physiol Renal Physiol</source><year>2012</year><volume>302</volume><issue>2</issue><fpage>F264</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00442.2010</pub-id><pub-id pub-id-type="pmid">21993890</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthesen</surname><given-names>SK</given-names></name><name><surname>Larsen</surname><given-names>T</given-names></name><name><surname>Lauridsen</surname><given-names>TG</given-names></name><name><surname>Vase</surname><given-names>H</given-names></name><name><surname>Gjorup</surname><given-names>PH</given-names></name><name><surname>Nykjaer</surname><given-names>KM</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Effect of amiloride and spironolactone on renal tubular function, ambulatory blood pressure, and pulse wave velocity in healthy participants in a double-blinded, randomized, placebo-controlled, crossover trial</article-title><source>Clin Exp Hypertens</source><year>2012</year><volume>34</volume><issue>8</issue><fpage>588</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.3109/10641963.2012.681730</pub-id><pub-id pub-id-type="pmid">22591021</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>RS</given-names></name><name><surname>Bentzen</surname><given-names>H</given-names></name><name><surname>Bech</surname><given-names>JN</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans</article-title><source>Am J Physiol Renal Physiol</source><year>2001</year><volume>280</volume><issue>5</issue><fpage>F860</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11292629</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>H</given-names></name><name><surname>Kwon</surname><given-names>TH</given-names></name><name><surname>Vinnikova</surname><given-names>AK</given-names></name><name><surname>Masilamani</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>HL</given-names></name><name><surname>Fr&#x000f8;kiaer</surname><given-names>J</given-names></name><name><surname>Knepper</surname><given-names>MA</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name></person-group><article-title>Immunocytochemical and immunoelectron microscopic localization of alpha-, beta-, and gamma-ENaC in rat kidney</article-title><source>Am J physiol Renal Physiol</source><year>2001</year><volume>280</volume><issue>6</issue><fpage>F1093</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">11352848</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>EB</given-names></name><name><surname>Danielsen</surname><given-names>H</given-names></name><name><surname>Spencer</surname><given-names>ES</given-names></name></person-group><article-title>Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension</article-title><source>Eur J Clin Pharmacol</source><year>1984</year><volume>26</volume><issue>5</issue><fpage>543</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/BF00543482</pub-id><pub-id pub-id-type="pmid">6468469</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>EB</given-names></name><name><surname>Eiskjaer</surname><given-names>H</given-names></name><name><surname>Madsen</surname><given-names>B</given-names></name><name><surname>Danielsen</surname><given-names>H</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>CB</given-names></name></person-group><article-title>Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease</article-title><source>Nephrol Dial Transplant</source><year>1993</year><volume>8</volume><issue>10</issue><fpage>1064</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">8272217</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoaf</surname><given-names>SE</given-names></name><name><surname>Bricmont</surname><given-names>P</given-names></name><name><surname>Mallikaarjun</surname><given-names>S</given-names></name></person-group><article-title>Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects</article-title><source>Int J Clin Pharmacol Ther</source><year>2012</year><volume>50</volume><fpage>150</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.5414/CP201621</pub-id><pub-id pub-id-type="pmid">22257581</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoaf</surname><given-names>SE</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bricmont</surname><given-names>P</given-names></name><name><surname>Mallikaarjun</surname><given-names>S</given-names></name></person-group><article-title>Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2007</year><volume>47</volume><fpage>1498</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1177/0091270007307877</pub-id><pub-id pub-id-type="pmid">17925589</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>PR</given-names></name><name><surname>McNeely</surname><given-names>EB</given-names></name><name><surname>Lin</surname><given-names>TE</given-names></name><name><surname>Adams</surname><given-names>KF</given-names></name><name><surname>Patterson</surname><given-names>JH</given-names></name></person-group><article-title>Review of tolvaptan&#x02019;s pharmacokinetic and pharmacodynamic properties and drug interactions</article-title><source>J Clin Med</source><year>2014</year><volume>3</volume><issue>4</issue><fpage>1276</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3390/jcm3041276</pub-id><pub-id pub-id-type="pmid">26237603</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Frank</surname><given-names>M</given-names></name><name><surname>Wuerzner</surname><given-names>G</given-names></name><name><surname>Peyrard</surname><given-names>S</given-names></name><name><surname>Bankir</surname><given-names>L</given-names></name><name><surname>Jeunemaitre</surname><given-names>X</given-names></name><name><surname>Azizi</surname><given-names>M</given-names></name></person-group><article-title>Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><issue>4</issue><fpage>753</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2215/CJN.06540810</pub-id><pub-id pub-id-type="pmid">21233458</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauridsen</surname><given-names>TG</given-names></name><name><surname>Vase</surname><given-names>H</given-names></name><name><surname>Bech</surname><given-names>JN</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Direct effect of methylprednisolone on renal sodium and water transport via the principal cells in the kidney</article-title><source>Eur J Endocrinol</source><year>2010</year><volume>162</volume><fpage>961</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1530/EJE-10-0030</pub-id><pub-id pub-id-type="pmid">20203161</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthesen</surname><given-names>SK</given-names></name><name><surname>Larsen</surname><given-names>T</given-names></name><name><surname>Vase</surname><given-names>H</given-names></name><name><surname>Lauridsen</surname><given-names>TG</given-names></name><name><surname>Pedersen</surname><given-names>EB</given-names></name></person-group><article-title>Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans</article-title><source>Scand J Clin Lab Invest</source><year>2012</year><volume>72</volume><issue>1</issue><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.3109/00365513.2011.635216</pub-id><pub-id pub-id-type="pmid">22149452</pub-id></element-citation></ref></ref-list></back></article>